Pharmicell Co Ltd
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impotence; and Hearticellgram_AMI, a cardiac disease drug. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, a cell culture medium; and PharmiSTEM culture medium for mesenchymal stem cells, as well as clinical development and commercialization services for new drugs. Further, it operates stem cell bank under Twelve brand name; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
If you'd bought from year…
Same habit, different start year. Each row shows what a constant habit's worth of 005690-KS would be worth today, had you started buying at that point in the asset's history.
| Started | $6/day$6/day coffee | $42/wk$42/week coffee |
|---|---|---|
| Year 1 (2000) — listing | $535,485 13.5× | $761,987 13.2× |
| Year 6 (2005) | $203,187 6.4× | $295,399 6.3× |
| Year 11 (2010) | $54,487 2.3× | $80,862 2.3× |
| Year 16 (2015) | $32,397 1.9× | $48,199 1.9× |
| Year 21 (2020) | $14,041 1.5× | $20,957 1.5× |
| Year 26 (2025) | $2,423 1.2× | $3,670 1.2× |
Repeated investment, no fees, dividends reinvested. $6/day coffee = $180 / month equivalent.
Popular scenarios with 005690
For illustration only — not investment advice. Past performance is not indicative of future results.